The Intersection of TNF, IBD and the Microbiome. Academic Article

abstract

• Inflammatory bowel disease (IBD), comprised of Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of multifactorial etiology and risk factors. Currently, one of the most effective treatments for IBD is the use of Tumor Necrosis Factor (TNF) functional inhibitor drugs, however, this treatment can cause adverse reactions and has a relatively large percentage of incomplete or non-responders. This lack of response may be related to differences in patients' gut microbiomes prior to and after disease initiation or treatment. Recent observations in our lab using a rodent model of IBD support the theory that TNF drives acute colitis, but also that the microbiome differs in association with TNF production and colitis severity. Studies such as this and others provide new insights into host-microbiome interactions associated with colitis that can lead to new therapies to prevent or treat the disease.

authors

• Jones-Hall, Yava

published proceedings

• Gut Microbes

altmetric score

• 8.33

author list (cited authors)

• Jones-Hall, Y. L., & Nakatsu, C. H.

citation count

• 42

complete list of authors

• Jones-Hall, Yava L||Nakatsu, Cindy H

publication date

• January 2016

publisher

• Taylor & Francis  Publisher

published in

• Gut Microbes  Journal

keywords

• Animals
• CD4-Positive T-Lymphocytes
• Colitis
• Colitis, Ulcerative
• Crohn Disease
• Cytokines
• Disease Models, Animal
• Firmicutes
• Gastrointestinal Microbiome
• Humans
• Immunity, Mucosal
• Inflammatory Bowel Disease
• Mice
• Microbiota
• Mouse Model
• Symbiosis
• Tnbs
• Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha

PubMed Central ID

• 26939853

Digital Object Identifier (DOI)

• 10.1080/19490976.2015.1121364

start page

• 58

end page

• 62

volume

• 7

issue

• 1

URL

• http://dx.doi.org/10.1080/19490976.2015.1121364